KarriereInvestor RelationsPresseCOVID-19
Login
  1. Startseite
  2. Medizinische Bildgebung
  3. Nuklearmedizin / Molekulare Bildgebung
  4. MI Trends and Innovations
  5. The Value of Molecular Imaging for Prostate Cancer
Clinical molecular imaging prostate image

The Value of Molecular Imaging for Prostate CancerMolecular imaging without compromise

  • Facts & Figures
  • Clinical image gallery
  • Case studies
Contact Us

Prostate cancer facts and figures

prostate cancer facts and figures

Clinical image gallery

PET/CT in prostate cancer
Data courtesy of Prof. Dr. Drzezga, Clinic for Nuclear Medicine, University Hospital Cologne, Cologne, Germany.

Case studies

A 68Ga PSMA study, performed on Biograph Vision, aides in the visualization of bladder invasion and pelvic lymph node metastases.

Detection of Bladder Invasion and Pelvic Lymph Node Metastases in a Patient with Primary Prostate Cancer

A 62-year-old man with primary prostate cancer, diagnosed on clinical examination and transrectal ultrasound, underwent 68Ga PSMA5 PET/CT for initial staging. The PET/CT study was performed on Biograph Vision™.

A 68Ga PSMA study, performed on Biograph Vision, aides in the visualization of a solitary lymph node metastasis in a patient with primary prostate cancer.

Detection of Solitary Pelvic Lymph Node Metastasis in a Patient with Primary Prostate Cancer

A 78-year-old male with a medical history of lower urinary tract symptoms, referred for primary staging of his newly-diagnosed Gleason 3+4 prostate cancer, underwent a 68Ga PSMA5 PET/CT for initial staging on Biograph Vision™.

A xSPECT Quant image quantifies a rib lesion on a SPECT/CT scan.

Differentiation of a rib benign lesion from a metastasis using xSPECT Quant

A 58-year-old patient with prostatic hypertrophy underwent a prostatectomy, which led to an incidental discovery of adenocarcinoma of the prostate. After initial planar acquisitions were conducted, a subsequent SPECT/CT examination using xSPECT Bone™ and xSPECT Quant™ was administered for the thorax.

1Siegel, R., Miller, K. & Jemal, A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67, 7–30 (2017).

2Torre, LA., et al. Global cancer statistics, 2012, CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262.

3The tracer mentioned is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries.

4Please see indication and important safety information at www.mayoclinic.org

568Ga PSMA referenced herein is (are) not currently recognized by the US FDA as being safe and effective, and Siemens does not make any claims regarding its use.

Image data courtesy of WVU Medical Center, Morgantown, West Virginia, USA.